JP2009524591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009524591A5 JP2009524591A5 JP2008547549A JP2008547549A JP2009524591A5 JP 2009524591 A5 JP2009524591 A5 JP 2009524591A5 JP 2008547549 A JP2008547549 A JP 2008547549A JP 2008547549 A JP2008547549 A JP 2008547549A JP 2009524591 A5 JP2009524591 A5 JP 2009524591A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- compound
- halo
- independently selected
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 46
- 125000005843 halogen group Chemical group 0.000 claims 41
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 15
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000001118 alkylidene group Chemical group 0.000 claims 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 5
- -1 1,2-methylenedioxy Chemical group 0.000 claims 5
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000000003 Breakthrough pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000004404 Intractable Pain Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 *[C@]1C*=CCC1 Chemical compound *[C@]1C*=CCC1 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75292605P | 2005-12-21 | 2005-12-21 | |
| US79118106P | 2006-04-11 | 2006-04-11 | |
| US79979706P | 2006-05-12 | 2006-05-12 | |
| US83944406P | 2006-08-23 | 2006-08-23 | |
| PCT/US2006/048802 WO2007075895A2 (en) | 2005-12-21 | 2006-12-21 | Heterocyclic derivatives as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009524591A JP2009524591A (ja) | 2009-07-02 |
| JP2009524591A5 true JP2009524591A5 (cg-RX-API-DMAC7.html) | 2011-01-13 |
Family
ID=38050930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547549A Pending JP2009524591A (ja) | 2005-12-21 | 2006-12-21 | イオンチャネルのモジュレーターとしての複素環誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7799822B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2308872A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009524591A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080081178A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101365686A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006331608B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2633653A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL192184A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20083220L (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ569694A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008129821A (cg-RX-API-DMAC7.html) |
| SG (1) | SG181209A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200740803A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007075895A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200805338B (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| CA2622076A1 (en) * | 2005-09-09 | 2007-03-15 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| JP2009512717A (ja) * | 2005-10-21 | 2009-03-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルを調節するための誘導体 |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| EP2253615B1 (en) | 2007-08-22 | 2014-07-09 | AstraZeneca AB | Cyclopropyl amide derivatives |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
| MX2010005307A (es) * | 2007-11-13 | 2010-07-28 | Vertex Pharma | Derivados heterociclicos como moduladores de canales de iones. |
| CN101456860B (zh) * | 2007-12-10 | 2011-02-16 | 中国科学院上海药物研究所 | 4-[9-(6-氨基嘌呤基)]-2(s)-羟基丁酸甲酯的制备方法 |
| US8217064B2 (en) | 2007-12-20 | 2012-07-10 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| WO2009089277A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
| DE102008020785B4 (de) | 2008-04-25 | 2021-11-04 | Skw Stickstoffwerke Piesteritz Gmbh | Verwendung von einfachen Derivaten von 5-Amino-1,2,4-thiadiazol zur Hemmung bzw. Steuerung der Nitrifikation |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| WO2010002956A2 (en) | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US20110201623A1 (en) | 2010-02-18 | 2011-08-18 | Uczynski Michael A | Crystalline Form Of A Cyclopropyl Benzamide Derivative |
| JP2014532660A (ja) | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| JP2015535251A (ja) * | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物 |
| JP6422498B2 (ja) * | 2013-08-26 | 2018-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | アザスピロ［４．５］デカン誘導体及びその使用 |
| WO2015077905A1 (en) * | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| CN106795149B (zh) * | 2015-05-05 | 2019-09-24 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| TW201718557A (zh) * | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| WO2017201468A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| CN110896634A (zh) * | 2017-07-03 | 2020-03-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 |
| MX2020013317A (es) | 2018-06-13 | 2021-04-13 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y su uso como agentes terapeuticos. |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| WO2020047312A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3143666C (en) | 2019-06-18 | 2024-06-11 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
| PE20240213A1 (es) * | 2020-09-14 | 2024-02-16 | Genzyme Corp | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme |
| EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| WO2023028056A1 (en) * | 2021-08-24 | 2023-03-02 | Genentech, Inc. | 3-amino piperidyl sodium channel inhibitors |
| JP2025503737A (ja) | 2022-01-18 | 2025-02-04 | メイズ セラピューティクス， インコーポレイテッド | Ａｐｏｌ１阻害剤及び使用方法 |
| WO2024249254A2 (en) * | 2023-05-26 | 2024-12-05 | Maze Therapeutics, Inc. | Methods of using apol1 inhibitors |
| CN117326903B (zh) * | 2023-09-27 | 2025-05-02 | 常州大学 | 一种高立体选择性合成n-烷基化吲哚衍生物的方法 |
| TW202530205A (zh) * | 2023-10-31 | 2025-08-01 | 加拿大商再諾製藥公司 | 經取代之芳基磺醯胺及其組合物及用途 |
| CN117384091B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类酰胺衍生物、合成方法及用途 |
| WO2025245351A1 (en) * | 2024-05-22 | 2025-11-27 | Xenon Pharmaceuticals Inc. | Substituted aryl sulfonamides and compositions and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130753C (cg-RX-API-DMAC7.html) * | 1965-10-19 | |||
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| ATE296811T1 (de) * | 1997-07-11 | 2005-06-15 | Smithkline Beecham Plc | Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| CA2539227A1 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| SE0302570D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| JP4473764B2 (ja) * | 2005-03-31 | 2010-06-02 | タカラベルモント株式会社 | 椅子昇降用油圧装置 |
| EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| MX2007015726A (es) * | 2005-06-09 | 2008-03-04 | Vertex Pharma | Derivados de indano como moduladores de canales ionicos. |
| CA2622076A1 (en) * | 2005-09-09 | 2007-03-15 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| WO2007047474A2 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| JP2009512717A (ja) * | 2005-10-21 | 2009-03-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルを調節するための誘導体 |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
-
2006
- 2006-12-21 TW TW095148248A patent/TW200740803A/zh unknown
- 2006-12-21 US US11/643,622 patent/US7799822B2/en not_active Expired - Fee Related
- 2006-12-21 ZA ZA200805338A patent/ZA200805338B/xx unknown
- 2006-12-21 NZ NZ569694A patent/NZ569694A/en not_active IP Right Cessation
- 2006-12-21 JP JP2008547549A patent/JP2009524591A/ja active Pending
- 2006-12-21 EP EP10186696A patent/EP2308872A1/en not_active Withdrawn
- 2006-12-21 CA CA002633653A patent/CA2633653A1/en not_active Abandoned
- 2006-12-21 NZ NZ593074A patent/NZ593074A/en not_active IP Right Cessation
- 2006-12-21 WO PCT/US2006/048802 patent/WO2007075895A2/en not_active Ceased
- 2006-12-21 EP EP06845951A patent/EP1963281A2/en not_active Withdrawn
- 2006-12-21 AU AU2006331608A patent/AU2006331608B2/en not_active Expired - Fee Related
- 2006-12-21 CN CNA2006800525107A patent/CN101365686A/zh active Pending
- 2006-12-21 KR KR1020087017835A patent/KR20080081178A/ko not_active Ceased
- 2006-12-21 EP EP10186698A patent/EP2316829A1/en not_active Withdrawn
- 2006-12-21 RU RU2008129821/04A patent/RU2008129821A/ru not_active Application Discontinuation
-
2008
- 2008-06-15 IL IL192184A patent/IL192184A0/en unknown
- 2008-07-21 NO NO20083220A patent/NO20083220L/no not_active Application Discontinuation
-
2010
- 2010-07-27 US US12/844,047 patent/US8163720B2/en active Active
-
2011
- 2011-04-21 SG SG2011029162A patent/SG181209A1/en unknown
-
2012
- 2012-03-14 US US13/419,936 patent/US8309587B2/en active Active
- 2012-10-02 US US13/633,478 patent/US8586589B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524591A5 (cg-RX-API-DMAC7.html) | ||
| RU2008129821A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2008540661A5 (cg-RX-API-DMAC7.html) | ||
| JP2009511599A5 (cg-RX-API-DMAC7.html) | ||
| JP2008543785A5 (cg-RX-API-DMAC7.html) | ||
| DK2026775T3 (en) | USE OF SYK tyrosine kinase inhibitors for treating cell proliferative DISORDERS | |
| JP2022119990A (ja) | アポトーシス誘発剤 | |
| JP7652865B2 (ja) | Ｒｏｃｋ阻害剤としての重水素化合物 | |
| WO2022230912A1 (ja) | 置換トリアジン化合物 | |
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| CA2684169A1 (en) | Smac mimetic dimers and trimers useful as anti-cancer agents | |
| RU2008118350A (ru) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов | |
| RU2006138040A (ru) | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ | |
| JP2013505945A5 (cg-RX-API-DMAC7.html) | ||
| TW200918528A (en) | DNA-PK inhibitors | |
| WO2005063241A1 (ja) | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 | |
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| KR20170102885A (ko) | 삼환성 스피로 화합물 | |
| JP2011511022A5 (cg-RX-API-DMAC7.html) | ||
| JP2009507851A5 (cg-RX-API-DMAC7.html) | ||
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| JP5980684B2 (ja) | ３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド化合物および腫瘍処置におけるそれらの使用 | |
| JP2008540666A5 (cg-RX-API-DMAC7.html) | ||
| RU2011108485A (ru) | Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств |